Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B

Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a biologics license application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for approval of BAX 326, a recombinant factor IX (rFIX) protein being investigated for the treatment and prophylaxis of bleeding episodes for patients over 12 years of age with hemophilia B.

Hemophilia B, also known as Christmas disease, is the second most common type of hemophilia and results from insufficient amounts of clotting factor IX, a naturally occurring protein in blood that helps to control bleeding. Approximately 25,000 people worldwide, including more than 4,000 in the U.S., have been diagnosed with hemophilia B.

The BLA filing is based on results from a global Phase III study conducted in 10 countries around the world. The prospective, controlled, multicenter study evaluated the pharmacokinetics, efficacy, safety and immunogenicity of BAX 326 in 73 patients with severe or moderately severe hemophilia B previously treated with other factor IX therapy. The study met its primary objectives and the company plans to present the complete data from the study in late 2012. Baxter expects to file its application for BAX 326 in Europe in 2013.

''Hemophilia B patients have relatively limited options for their treatment today, with only one commercially available recombinant (genetically engineered) protein. As part of our long-standing commitment to the hemophilia community, we continue to pursue new potential treatment options like BAX 326 to support patients with this debilitating disease,'' said Prof. Hartmut J. Ehrlich, M.D., vice president of global research and development in Baxter's BioScience business.

In select countries, Baxter currently offers a plasma-derived factor IX treatment, Immunine [Factor IX Concentrate (Human)], for patients with hemophilia B, which has more than 16 years of patient experience in Europe and Latin America. In addition, Baxter recently announced a partnership with Chatham Therapeutics, LLC to develop a gene therapy based treatment for hemophilia B. Gene therapy could represent another important first for the community as an innovative potential therapy for hemophilia B treatment.

Source:

 Baxter International Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2019, June 19). Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B. News-Medical. Retrieved on February 04, 2023 from https://www.news-medical.net/news/20120905/Baxter-seeks-FDA-BLA-approval-for-BAX-326-rFIX-protein-to-treat-hemophilia-B.aspx.

  • MLA

    Baxter International Inc.. "Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B". News-Medical. 04 February 2023. <https://www.news-medical.net/news/20120905/Baxter-seeks-FDA-BLA-approval-for-BAX-326-rFIX-protein-to-treat-hemophilia-B.aspx>.

  • Chicago

    Baxter International Inc.. "Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B". News-Medical. https://www.news-medical.net/news/20120905/Baxter-seeks-FDA-BLA-approval-for-BAX-326-rFIX-protein-to-treat-hemophilia-B.aspx. (accessed February 04, 2023).

  • Harvard

    Baxter International Inc.. 2019. Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B. News-Medical, viewed 04 February 2023, https://www.news-medical.net/news/20120905/Baxter-seeks-FDA-BLA-approval-for-BAX-326-rFIX-protein-to-treat-hemophilia-B.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO